中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

95 records (took 0.033 seconds)

    DNA Vaccines Encoding Antigen Linked to a Domain That Binds CD40
    31.
    发明申请
    DNA Vaccines Encoding Antigen Linked to a Domain That Binds CD40 审中-公开
    编码与绑定CD40的域相关的抗原的DNA疫苗

    公开(公告)号：US20090074814A1

    公开(公告)日：2009-03-19

    申请号：US12233750

    申请日：2008-09-19

    Applicant: Jeffrey A. Ledbetter ,  Martha Hayden-Ledbetter

    Inventor： Jeffrey A. Ledbetter ,  Martha Hayden-Ledbetter

    IPC: A61K39/21 ,  A61K39/00 ,  C12N15/00

    CPC classification number: C07K14/005 ,  A61K39/00 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/6031 ,  C07K2319/00 ,  C12N2740/16122 ,  C12N2740/16134

    Abstract: Vaccines that target one or more antigens to a cell surface receptor improve the antigen-specific humoral and cellular immune response. Antigen(s) linked to a domain that binds to a cell surface receptor are internalized, carrying antigen(s) into an intracellular compartment where the antigen(s) are digested into peptides and loaded onto MHC molecules. T cells specific for the peptide antigens are activated, leading to an enhanced immune response. The vaccine may comprise antigen(s) linked to a domain that binds at least one receptor or a DNA plasmid encoding antigen(s) linked to a domain that binds at least one receptor. A preferred embodiment of the invention targets HIV-1 env antigen to the CD40 receptor, resulting in delivery of antigen to CD40 positive cells, and selective activation of the CD40 receptor on cells presenting HIV-1 env antigens to T cells.

    Abstract translation: 将一种或多种抗原靶向细胞表面受体的疫苗可改善抗原特异性体液和细胞免疫应答。 与结合细胞表面受体的结构域连接的抗原被内化，将抗原携带到细胞内隔室中，其中抗原被消化成肽并加载到MHC分子上。 对肽抗原特异性的T细胞被激活，导致增强的免疫应答。 疫苗可以包含连接到结合至少一种受体的结构域的抗原或编码与结合至少一种受体的结构域连接的抗原的DNA质粒。 本发明的优选实施方案将HIV-1 env抗原靶向CD40受体，导致抗原递送至CD40阳性细胞，以及将呈递HIV-1 env抗原的细胞上的CD40受体选择性激活至T细胞。

    Method of regulating cellular processes mediated by B7 and CD28
    33.
    发明授权
    Method of regulating cellular processes mediated by B7 and CD28 失效
    调节由B7和CD28介导的细胞过程的方法

    公开(公告)号：US06641809B1

    公开(公告)日：2003-11-04

    申请号：US08219200

    申请日：1994-03-29

    Applicant: Peter S. Linsley ,  Jeffrey A. Ledbetter ,  Nitin K. Damle ,  William Brady

    Inventor： Peter S. Linsley ,  Jeffrey A. Ledbetter ,  Nitin K. Damle ,  William Brady

    IPC: A61K3817

    CPC classification number: C07K14/70532 ,  A61K38/00 ,  C07K14/705 ,  C07K14/70521 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/2827 ,  C07K2317/73 ,  C07K2319/00 ,  G01N33/56972 ,  Y10S514/885 ,  Y10S530/866 ,  Y10S530/867 ,  Y10S530/868

    Abstract: The invention identifies the B7 antigen as a ligand that is reactive with the CD28 receptor on T cells. Fragments and derivatives of the B7 antigen and CD28 receptor, including fusion proteins having amino acid sequences corresponding to the extracellular domains of B7 or CD28 joined to amino acid sequences encoding portions of human immunoglobulin C&ggr;1, are described. Methods are provided for using B7 antigen, its fragments and derivatives, and the CD28 receptor, its fragments and derivatives, as well as antibodies and other molecules reactive with B7 antigen and/or the CD28 receptor, to regulate CD28 positive T cell responses, and immune responses mediated by T cells. The invention also includes an assay method for detecting ligands reactive with cellular receptors mediating intercellular adhesion.

    Abstract translation: 本发明将B7抗原鉴定为与T细胞上的CD28受体反应的配体。 描述了B7抗原和CD28受体的片段和衍生物，包括与编码部分人免疫球蛋白Cgamma1的氨基酸序列连接的与B7或CD28的细胞外结构域相对应的氨基酸序列的融合蛋白。 提供了使用B7抗原，其片段和衍生物以及CD28受体，其片段和衍生物以及与B7抗原和/或CD28受体反应的抗体和其它分子调节CD28阳性T细胞应答的方法，以及 由T细胞介导的免疫应答。 本发明还包括检测与介导细胞间粘附的细胞受体反应的配体的测定方法。

    CD40 receptor ligands
    34.
    发明授权
    CD40 receptor ligands 失效
    CD40受体配体

    公开(公告)号：US06472510B1

    公开(公告)日：2002-10-29

    申请号：US08338975

    申请日：1994-11-14

    Applicant: Alejandro A. Aruffo ,  Jeffrey A. Ledbetter ,  Ivan Stamenkovic ,  Randolph Noelle

    Inventor： Alejandro A. Aruffo ,  Jeffrey A. Ledbetter ,  Ivan Stamenkovic ,  Randolph Noelle

    IPC: C07K14705

    CPC classification number: C07K16/2875 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/70578 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/30 ,  Y10S530/866

    Abstract: The present invention relates to a counter-receptor, termed CD40CR, for the CD40 B-cell antigen, and to soluble ligands for this receptor, including fusion molecules comprising at least a portion of CD40 protein. It is based, at least in part, on the discovery that a soluble CD40/immunoglobulin fusion protein was able to inhibit helper T-cell mediated B-cell activation by binding to a novel 39 kD protein receptor on helper T-cell membranes. The present invention provides for a substantially purified CD40CR receptor; for soluble ligands of CD40CR, including antibodies as well as fusion molecules comprising at least a portion of CD40 protein; and for methods of controlling B-cell activation which may be especially useful in the treatment of allergy or autoimmune disease.

    Abstract translation: 本发明涉及用于CD40B细胞抗原的称为CD40CR的反受体，以及该受体的可溶性配体，包括至少包含一部分CD40蛋白的融合分子。 至少部分基于这样一个发现，即可溶性CD40 /免疫球蛋白融合蛋白能够通过结合辅助性T细胞膜上的新型39kD蛋白受体来抑制辅助T细胞介导的B细胞活化。 本发明提供了基本纯化的CD40CR受体; 用于CD40CR的可溶性配体，包括抗体以及包含至少一部分CD40蛋白的融合分子; 以及用于控制B细胞活化的方法，其可能特别可用于治疗过敏或自身免疫性疾病。

    Inhibition of tumor cell growth by administration of B7-transfected cells
    35.
    发明授权
    Inhibition of tumor cell growth by administration of B7-transfected cells 失效
    通过施用B7转染的细胞抑制肿瘤细胞生长

    公开(公告)号：US06183734B2

    公开(公告)日：2001-02-06

    申请号：US08402405

    申请日：1995-03-10

    Applicant: Lieping Chen ,  Ingegerd Hellström ,  Karl Erik Hellström ,  Jeffrey A. Ledbetter ,  Peter S. Linsley

    Inventor： Lieping Chen ,  Ingegerd Hellström ,  Karl Erik Hellström ,  Jeffrey A. Ledbetter ,  Peter S. Linsley

    IPC: A01N6300

    CPC classification number: C07K14/4748 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  A61K48/00 ,  A61K2039/5156

    Abstract: The present invention is directed to a method of inhibiting tumor cell growth. Tumor cells from a pateint are recombinantly engineered to express the B7 surface protein and these cells are then readminsistered to the pateint. The presence of the B7 molecule on the tumor cell surface stimulates a broad immunologic response against both the B7-transfected and non-transfected tumor cells and results in the immunologic killing of localized and metastatic tumor cells. B7 transfection of the tumor cells, or cell membranes, serves as a stimulant to engender a potent immunologic response against the surface antigens present on the tumor cells.

    Abstract translation: 本发明涉及一种抑制肿瘤细胞生长的方法。 来自pateint的肿瘤细胞被重组工程化以表达B7表面蛋白质，然后将这些细胞读取到pateint。 B7分子在肿瘤细胞表面的存在刺激对B7转染和未转染的肿瘤细胞的广泛的免疫应答，并导致局部和转移性肿瘤细胞的免疫学杀伤。 肿瘤细胞或细胞膜的B7转染作为刺激物，对肿瘤细胞上存在的表面抗原产生有效的免疫应答。

Patent Agency Ranking